stock was falling Thursday as sales in the pharmaceutical company’s much-hyped obesity drug came up short. Fourth-quarter earnings, however, did crush estimates.
There’s still too much risk in stock and bond markets. Earn this easy 4.5% return while you wait for stability, says trader who hit 2 big calls in 2022.
By 
Comments